Full Coverage of this storyMcKesson to Spin Off Medical-Surgical Company
By Katherine Hamilton
This Medical Supplies Distributor Dodges A Tariff Bullet
By Kimberley Koenig
McKesson Gets Drugs to Patients. Buy the Stock for Healthy Returns.
By Teresa Rivas & Allen Root
McKesson Faces Faith Accommodation Trial Over Covid Vaccine Rule
By Patrick Dorrian
McKesson misses third-quarter revenue estimates
By Christy Santhosh & Shilpi Majumdar
McKesson, Oracle fight for Veradigm
By Claire Rychlewski
Texas Health Plano's $343 Million Expansion and McKesson's Discrimination Settlement
By Victor Sanchez
The Power of Proximity Sparked Deeper Dialogue to Help Health Systems Achieve More at THMA's Spring 2025 Pharmacy Collaborative | Prescribed Perspectives
By Heather Easterling
Anti-monopoly advocates urge FTC to block McKesson, Cardinal Health's big-ticket oncology acquisitions
By Dave Muoio
McKesson stock cut to Neutral at Baird (NYSE:MCK)
By Dulan Lokuwithana
Baltimore to take drug distributors to trial over opioids
By Brendan Pierson
McKesson emerges as D-FW’s largest public company
By Kyle Arnold & Andrew Long
McKesson Shares New Initiative to Support Advocacy Efforts for the Pharmacy Profession
By Kennedy Ferruggia
What are the Top McKesson Government Contracts?
By Siegfried Cagat
Container Services to relocate to former McKesson plant
By Nicholas Vercilla
S&P 500 Gains and Losses Today: McKesson Falls Amid Plans To Exit Canada Businesses
By Michael Bromberg